Mesoblast (MESO) Liabilities and Shareholders Equity (2015 - 2025)

Mesoblast (MESO) has reported Liabilities and Shareholders Equity for 11 consecutive years, with $782.3 million the latest figure, recorded in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 19.74% year-over-year to $782.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.9 billion (up 8.54% YoY) and the FY2025 annual result came in at $784.7 million, up 17.27% from the prior year.
• Liabilities and Shareholders Equity steadied at $782.3 million in Q4 2025 per MESO's latest filing, from $784.7 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for MESO reached as high as $784.7 million in Q2 2025 and fell as low as $650.4 million in Q1 2023.
• A 5-year average of $700.9 million and a median of $681.7 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity decreased 11.09% — and 2025, when it grew 19.74%.
• Year by year, Liabilities and Shareholders Equity stood at $704.4 million in 2021, then decreased by 5.16% to $668.1 million in 2022, then grew by 0.33% to $670.3 million in 2023, then decreased by 2.53% to $653.3 million in 2024, then advanced by 19.74% to $782.3 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $782.3 million, $784.7 million, and $653.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.